| 2025-12-05 |
详情>>
股本变动：
变动后总股本5171.85万股
变动原因 ▼▲
- 原因：
- Common Stock offered 6,000,000 shares by the company
|
| 2025-12-03 |
复牌提示：
2025-12-03 10:17:31 停牌，复牌日期 2025-12-03 10:22:31
|
| 2025-11-10 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-1.64美元,归母净利润-7487.3万美元,同比去年增长-124.5%
|
| 2025-11-10 |
财报披露：
美东时间 2025-11-10 盘后发布财报
|
| 2025-08-11 |
详情>>
业绩披露：
2025年中报每股收益-1.1美元,归母净利润-5030.24万美元,同比去年增长-141.91%
|
| 2025-05-14 |
详情>>
业绩披露：
2025年一季报每股收益-0.53美元,归母净利润-2439.16万美元,同比去年增长-149.04%
|
| 2025-04-08 |
股东大会：
将于2025-05-22召开股东大会
会议内容 ▼▲
- 1.To elect the eight nominees named in this proxy statement to the Company’s board of directors to serve for a one-year term expiring at our 2026 Annual Meeting of Stockholders;
2.To ratify the appointment of Rose, Snyder & Jacobs LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025;
3.To approve the adoption of the Capricor Therapeutics 2025 Equity Incentive Plan;
4.To approve, by non-binding advisory vote, the resolution approving named executive officer compensation;
5.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2025-03-26 |
详情>>
业绩披露：
2024年年报每股收益-1.15美元,归母净利润-4046.72万美元,同比去年增长-81.57%
|
| 2025-03-03 |
详情>>
内部人交易：
Litvack Frank等共交易6笔
|
| 2024-11-14 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-1.04美元,归母净利润-3335.06万美元,同比去年增长-54.94%
|
| 2024-08-08 |
详情>>
业绩披露：
2024年中报每股收益-0.66美元,归母净利润-2079.39万美元,同比去年增长-37.39%
|
| 2024-05-14 |
详情>>
业绩披露：
2024年一季报每股收益-0.31美元,归母净利润-979.41万美元,同比去年增长-26.08%
|
| 2024-04-01 |
股东大会：
将于2024-05-14召开股东大会
会议内容 ▼▲
- 1.To elect the nine (9) nominees named in this proxy statement to the Company’s board of directors to serve for a one-year term expiring at our 2025 Annual Meeting of Stockholders;
2.To ratify the appointment of Rose, Snyder & Jacobs LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024;
3.To approve, by non-binding advisory vote, the resolution approving named executive officer compensation;
4.To approve an amendment in the form set forth on Annex A to this proxy statement (the “Charter Amendment”) to the Company’s Certificate of Incorporation, as amended from time to time (the “Certificate of Incorporation”) to increase the number of authorized shares of our common stock from 50,000,000 to 100,000,000;
5.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2024-03-11 |
详情>>
业绩披露：
2023年年报每股收益-0.83美元,归母净利润-2228.75万美元,同比去年增长23.20%
|
| 2023-11-14 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.85美元,归母净利润-2152.55万美元,同比去年增长-1.07%
|
| 2023-08-08 |
详情>>
业绩披露：
2023年中报每股收益-0.6美元,归母净利润-1513.48万美元,同比去年增长-1.39%
|
| 2023-04-17 |
股东大会：
将于2023-06-12召开股东大会
会议内容 ▼▲
- 1.To elect the seven (7) nominees named in this proxy statement to the Company’s board of directors to serve for a one-year term expiring at our 2024 Annual Meeting of Stockholders;
2.To ratify the appointment of Rose, Snyder & Jacobs LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023;
3.To approve, by non-binding advisory vote, the resolution approving named executive officer compensation;
4.To consider and act upon approval of an amendment to the Certificate of Incorporation regarding officer exculpation;
5.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2022-04-12 |
股东大会：
将于2022-06-03召开股东大会
会议内容 ▼▲
- 1.To elect the seven (7) nominees named in this proxy statement to the Company’s board of directors to serve until the 2023 Annual Meeting of Stockholders;
2.To ratify the appointment of Rose, Snyder & Jacobs LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022;
3.To approve, by non-binding advisory vote, the resolution approving named executive officer compensation;
4.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-20 |
股东大会：
将于2021-06-11召开股东大会
会议内容 ▼▲
- 1.To elect the six (6) nominees to the Company’s board of directors to serve until the 2022 Annual Meeting of Stockholders;
2.To ratify the appointment of Rose, Snyder & Jacobs LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2021;
3.To approve the adoption of the Capricor Therapeutics 2021 Equity Incentive Plan;
4.To approve, by non-binding advisory vote, the resolution approving named executive officer compensation;
5.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2020-04-17 |
股东大会：
将于2020-06-05召开股东大会
会议内容 ▼▲
- 1.To elect the six (6) nominees to the Company’s board of directors to serve until the 2021 Annual Meeting of Stockholders;
2.To ratify the appointment of Rose, Snyder & Jacobs LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2020;
3.To approve the adoption of the Capricor Therapeutics 2020 Equity Incentive Plan;
4.To approve, by non-binding advisory vote, the resolution approving named executive officer compensation;
5.To approve, by non-binding advisory vote, the frequency of future non-binding advisory votes on resolutions approving named executive officer compensation;
6.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2019-06-05 |
详情>>
拆分方案：
每10.0000合并分成1.0000股
|
| 2019-04-30 |
股东大会：
将于2019-05-29召开股东大会
会议内容 ▼▲
- 1.To elect the six (6) nominees to the Company’s board of directors to serve until the 2020 Annual Meeting of Stockholders;
2.To ratify the appointment of Rose, Snyder & Jacobs LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019;
3.To approve an amendment to our Amended and Restated Certificate of Incorporation to effect a reverse stock split of our common stock at a ratio in the range of 1-for-3 to 1-for-15, with such ratio to be determined in the discretion of our board of directors and with such reverse stock split to be effected at such time and date, if at all, as determined by our board of directors in its sole discretion;
4.To authorize an adjournment of the meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposal 3;
5.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2018-04-26 |
股东大会：
将于2018-06-08召开股东大会
会议内容 ▼▲
- 1.To elect the seven (7) nominees to the Company’s board of directors to serve until the 2019 Annual Meeting of Stockholders;
2.To ratify the appointment of Rose, Snyder & Jacobs LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2018;
3.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2017-04-21 |
股东大会：
将于2017-06-14召开股东大会
会议内容 ▼▲
- 1. To elect the seven (7) nominees to the Company’s Board of Directors to serve until the 2018 Annual Meeting of Stockholders;
2. To ratify the appointment of Rose, Snyder & Jacobs LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2017;
3. To approve, by non-binding advisory vote, the resolution approving named executive officer compensation (“Say on Pay Vote”);
4. To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2016-04-28 |
股东大会：
将于2016-06-02召开股东大会
会议内容 ▼▲
- 1. To elect the eight (8) nominees to the Company’s Board of Directors to serve until the 2017 Annual Meeting of Stockholders;
2. To approve amendments to the Company’s 2012 Restated Equity Incentive Plan, as amended (the “2012 Plan”), to, among other things, increase the number of shares of common stock that may be issued under the 2012 Plan to equal the sum of 4,149,710 plus 2% of the outstanding shares of common stock of the Company as of December 31, 2015, with the number of shares that may be issued under the 2012 Plan automatically increasing thereafter on January 1 of each year, commencing with January 1, 2017, by 2% of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year (rounded down to the nearest whole share);
3. To ratify the appointment of Rose, Snyder & Jacobs LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2016;
4. To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|